Posted by Michael Wonder on 20 Sep 2022
XVIVO granted breakthrough device designation from the FDA for the liver assist device
20 September 2022 - XVIVO Perfusion has been granted breakthrough device designation from the US FDA for their liver assist device, indicated for ex vivo oxygenated machine perfusion for preservation of donor livers prior to transplantation.
The US is the largest liver transplant market globally with more than 8,600 livers transplanted in 2021.
